# **OVERVIEW AND UPDATE ON**



ROADSHOW PRESENTATION
JULY 2021

Executive Summary



# Beston: who we are and what we do

We are a dairy, dairy nutraceuticals and meat processing company based in South Australia We provide Australian and global customers with healthy choice dairy and meat proteins



#### **DAIRY**

Jervois and Murray Bridge, South Australia 90% of group revenue







# MEAT Shepparton, Victoria

10% of group revenue



Dice and grind ingredients

Premium hamburgers, meatballs

Retail products eg lamb shanks

Alternative meats

### Extracting more value from every litre of milk processed

Technology: Core operating assets supported by development of track and trace software

#### Where have we come from?

Founder led business

IPO August 2015

Three stage growth strategy requiring substantial investment to build productive capacity and achieve economies of scale

Initially China facing (ChAFTA), now focused on Australian dairy and meat markets


Brand building – 130+ awards for dairy product quality and innovation

Dairy nutraceuticals expansion to extract the "hidden value" from the "goodness of milk"

# Fastest growing food and beverage company in Australia<sup>1</sup>

Second fastest growing food and beverage company in Asia Pacific





# **Executing our strategic plan has** driven revenue growth since 2016

Fix, focus and build out the dairy assets

Increased milk supply to achieve:

- Capacity utilisation
- · Economies of scale

Built mozzarella plant, built brands and grown sales

Invested in people capabilities

Nutraceuticals production capacity increased

Upgraded and expanded production facilities at Provincial Food Group to grow sales of ready-to-eat meat meals


<sup>&</sup>lt;sup>1</sup> Report by Financial Times in conjunction with Nikkei Asia (Japan) and Statistica (Germany) on Asia's Top 500 Fastest Growing Companies 2016-2019

# BFC have built a strong sales book

#### Based on a reputation for quality dairy products and customer service

Malaysia, South Korea






completion of plant expansion

# **Dairy operations at Jervois**

Expansion of lactoferrin production facility adds significant value to the Jervois site




### Key drivers to deliver long term value creation



1 Estimate based on current operating assumptions

### Lactoferrin






# Components of Milk

3.5% protein

4.0% fat



https://youtu.be/DVb2\_x3iass Lactoferrin And COVID-19: Previous Evidence And Mechanism Against COVID-19 – YouTube

- Lactoferrin (Lf) is in cows milk in small quantities
- Lf is present in all human secretions (tears, saliva) and is in high concentrations in breast milk to support baby's development and immune system
- Bovine Lf is almost identical to human Lf
- The general immune supporting anti-bacterial and anti-viral properties of Lf have been known for many years. LF has been shown to inhibit viral impacts on the body through a number of studies.

#### Markets / Uses

- Infant formula
- Health supplements
- Immune support in medical settings eg cancer treatment
- Nutritional foods
- Personal care products

#### Demand

- World demand c. 500Tpa
- CAGR c.8%pa
- B2B sales. Pricing varies on quality and market requirements c. \$A1,000/kg
- Beston seeking c.70%pa volume sold under long term supply contracts

# **Lactoferrin Processing**



### Lactoferrin (Lf) capacity and quality is influenced by:

- Volume of Lf within the raw milk can be impacted by
  - Health of the cows
  - Timing within the lactation cycle
  - Generally follows the protein curve in milk
- · Processing technology and processing understanding can have a significant influence on Lf
  - Technology adopted for extraction efficiency not all Lf plants are the same
  - Process understanding not all processes are the same, some less efficient than others
  - Product quality can be influenced by the technology and process used


#### Beston Process

- Utilizes current best practice technology and processes to achieve high yielding Lf
- New product development pipeline working with technology suppliers on differentiating Lf products

#### Beston Team

- Industry experience with multiple Lf plant startups
- Onsite laboratory with expert staff that are able to provide an understanding to our operations team daily, for fine tuning of the process in real time







# **Lactoferrin: A whey protein**



An iron-binding glycoprotein which boosts the immune system with strong anti-microbial, anti-virus, anti-fungal properties



Delivered >95% purity Lactoferrin powder after freeze drying (showing the typical pink hue of the Lactoferrin protein)

#### Our nutritionals brand





Our nutritionals products

Our highest grade lactoferrin to support medical grade supplements and early life nutrition. 2 sub-products:

- >95% Lactoferrin
- >95% Lactoferrin GB (China) testing standard



# Trueferrin

>90% Lactoferrin for customers who do not require the higher grade of product for their application

#### Our retail brand



Immune+ drink: Berry flavoured lightly sparkling mineral water containing Lactoferrin Expected to be available in Drake's supermarkets in South Australia in coming weeks


Immune+ capsules: Target to launch late 2021

LifeX10: Ambient Lactoferrin, vitamins and mineral supplement

# Dairy facilities transformation nearing completion

Step-change in lactoferrin production underway

Fastest growing food and beverage company in Australia and second fastest in Asia Pacific region



Production and revenue increases driven by growing sales pipeline and enabled by increased milk supply

Volume growth and transition to higher value products

# **FY21 Highlights**

#### Execution of major milestones in a challenging COVID-19 impacted year





#### **Lactoferrin Expansion**

Initiated stages 1 and 2 of the lactoferrin expansion project to bring total capacity to 25 T from 180 ML milk; two extraction columns installed



#### **SA Government Grant**

Awarded \$2 million South Australian Government grant for Stage 2 lactoferrin expansion and secured second column for this stage



#### **Dairy Farms Sale**

Sold the dairy farms and redeployed the capital to pay down debt and increase ROCE



#### Jervois Infrastructure Review

Jervois infrastructure review identified requirements for the facility to operate more reliably as it moves toward 24/7 operations



#### **New Milk Supply**

~30% increase in milk supply including from Aurora Dairies on 1 September 2020



#### **Initiation of Rights Issue**

\$15.6m rights issue (completed in February) to fund Stage 2 lactoferrin expansion, and further upgrades of infrastructure at the Jervois facility



#### **Building Dairy Experience**

Key experience and skills in operations and nutraceuticals added to the dairy business



#### **IMA Termination**

Agreement to terminate the IMA received shareholder approval at EGM held on 28 May 2021; Termination on 28 August 2021

Poised to enter FY22 ready to capitalise on these fundamental changes to our business

# Well positioned heading into FY22

# Maiden profit to be delivered with strong operating cash flow



Operating reliability	<ul> <li>Teflon issues at Jervois mozzarella plant rectified</li> <li>Boiler control systems improved; replacement planned for FY22</li> <li>Multivac upgraded; replacement planned for FY22</li> <li>Maintenance regime overhauled; increased spend on preventative maintenance</li> <li>More staff with deep dairy experience</li> </ul>
Mozzarella sales	<ul> <li>~7,600 T (~50% of volume) under several longer-term supply agreements (~25% at start of FY21)</li> </ul>
Lactoferrin sales	<ul> <li>Plant expansion near final completion; product quality and yields exceeding expectations at this point in the project</li> <li>Significant new high margin revenue stream</li> <li>First order delivered</li> </ul>
Financial Position	<ul> <li>Operating cash flow positive</li> <li>FY22 activities fully funded</li> </ul>

# **FY22 Outlook**

### FY22 outlook is to deliver maiden profit with strong operating cash flows



Extracting more va	lue from every litre	of milk processed
--------------------	----------------------	-------------------

Measure	unit	FY21G <sup>1</sup>	FY21C <sup>2</sup>	FY22C <sup>2</sup>	Change	%	BFC Yields³
Milk	ML	142-148	145	155	10	7%	150
Mozzarella	MT	12,000- 13,000	12,090	14,368	2,278	19%	15,500
Lactoferrin	MT	3.0-4.0	3.0	16.5	13.5	450%	20.0
Group Sales	\$M	119-125	120	152	32	26%	
EBITDA	\$	ng	(17)	9	26	Large	•
NPAT	\$	ng	(15)	3	18	Large	•
Revenue/litre milk	\$/I	~0.76	0.76	0.90	0.14	19%	
Capex	\$	16-20	18	14	(4)	-20%	
Net Debt	\$	ng	21	30	9	40%	

~12% improved production yield with issues resolved. Higher yield adds ~\$14 million to earnings

Higher Lf sales add ~\$11 million to earnings

Improved yields, higher milk volume and Lf sales drive significantly higher results

<sup>1</sup> BFC Operational Guidance source: CEO Letter 21 May 21

<sup>2</sup> Analyst consensus as at June 21

<sup>3</sup> BFC Yields for 150ML milk processed based on current operating assumptions as per slide 3

# Future Value Extraction: Other whey proteins and their properties



We will expand the range of nutraceuticals made at Jervois and marketed under our brand



**Bi** lactive

Sweet whey powder is a lower value whey product in its current form, yet it has the most potential to drive further value within the business.

The whey proteins are highly valuable when extracted and purified.



#### Whey Concentrates - D40, D90, WPC, WPI

Used in a variety of products, Infant Formula, health and sports powders and drinks



#### Alpha-lactalbumin

Most abundant whey protein in human breast milk, high demand in infant formula as abundant in essential amino acids and replicates breast milk



#### Lactoperoxidase

An enzyme isolated during the Lactoferrin extraction process. It has anti-microbial properties and used in cosmetics, oral hygiene and medical cleaning products



#### Immunoglobulins (IgG, IgD, IgE, IgF, IgM)

Boosts immune function and promotes healthy gut environment by binding some pathogenic bacteria



#### Osteopontin

Found in high levels within human milk, this glycoprotein has strong calcium binding properties (low levels in bovine milk)



#### **Bovine Serum Albumin**

583 amino acids within its structure, used as a media in chemical labs with fatty acid binding properties



#### Beta-lactoglobulin

Rich in branched chain amino acids (BCAA) and used in sports nutrition, aids in muscle repair and growth

# Value proposition

Implementation of strategic imperatives have positioned Beston to deliver on its value proposition:

### **Entering FY22**

- Growing milk supply to ~155 ML in FY22 to underpin mozzarella and lactoferrin production
- Lactoferrin capacity increased to 25 Tpa, with global demand growing significantly.
   FY22 production expected to be ~20T.
- Streamlined Mozzarella production with remediation of supporting infrastructure nearing completion
- Built depth with new hires in dairy and nutraceuticals to ensure that skills are fitfor-purpose, match growth objectives, and support 24/7 operations
- Operating cash flow positive postcommissioning of lactoferrin project



### FY23 and beyond

- Leveraging assets to deliver growth in earnings – focus on Jervois milk supply 170ML-180ML pa
- Dairy nutraceuticals a key feature of Beston's earnings growth strategy to extract more value from the "goodness of milk" – starting with Lactoferrin
- Growing reputation as a reliable supplier of quality products
- Extracting more value from every litre
   of milk processed to generate strong
   positive operating cash flow and fund
   further investment in higher value
   products

Nutritional Food & Beverage market is estimated to grow from \$10bn to \$20bn by 2030

# **Disclaimer**

This presentation includes both information that is historical in character and information that consists of forward looking statements. Forward looking statements are not based on historical facts, but are based on current expectations of future results or events. The forward looking statements are subject to risks, stakeholder engagement, uncertainties and assumptions which could cause actual results, timing, or events to differ materially from the expectations described in such forward looking statements. Those risks and uncertainties include factors and risks specific to the industry in which Beston Global Food Company operates, any applicable legal requirements, as well as matters such as general economic conditions.

While Beston Global Food Company believes that the expectations reflected in the forward looking statements in this presentation are reasonable, neither Beston Global Food Company nor its directors or any other person named in the presentation can assure you that such expectations will prove to be correct or that implied results will be achieved. These forward looking statements do not constitute any representation as to future performance and should not be relied upon as financial advice of any nature. Any forward looking statement contained in this document is qualified by this cautionary statement.

# **Guidance disclaimer**



#### COVID-19

- COVID-19 continues to disrupt industries and economies globally
- Beston's guidance is based on current, known circumstances regarding COVID-19 and its impacts
- Guidance may be impacted adversely if COVID-19 continues longer than expected and/or has larger effects on demand and supply chains than presently anticipated



#### **Market conditions**

- General market conditions, such as market downturn, recession, industrial disputes and interest rates, could impact Beston's performance
- Certain risks are beyond the control of Beston; wherever possible Beston seeks to reduce or mitigate exposure to negative impacts of operating risks, whilst competing effectively in the market



#### **Operating performance**

- Dairy facility performance may be below expectations resulting in unplanned down time, higher repair costs and lost production
- Other key operating costs include electricity, gas, freight and insurance costs (some of which are not fixed and without forward contracts in place)



### Milk supply

- Milk supply is subject to agricultural risk, for example, a repeat of the drought conditions experienced in FY19 and FY20 could reduce the supply below contracted levels
- A reduction in milk supply may lead to increased milk prices



### **Lactoferrin facility**

- Risk of delay in delivery of already ordered long-lead items
- Construction delays could arise via importation issues or unforeseen site conditions
- Potential performance and reliability issues with new skim-based technology



#### Other risks

 Adverse weather events, new global pandemics, unplanned increases in costs, mechanical failures, human errors, industrial action and other unforeseen events, all have the potential to impact on Beston guidance